Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Sanofi India Limited

SANOFI · NSE · Healthcare · As of 4 Nov 2026Delayed / Sandbox EOD Data

₹3,450.80

+₹69.20 (+2.05%)(1D)

₹2,758.2052 Week Range₹4,775.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

77/100

Valuation

71/100

Quality

100/100

Growth

62/100

Health

96/100

Momentum

45/100

Valuation
71
Quality
100
Growth
62
Health
96
Momentum
45

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Sanofi India Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹3,450.8

Market cap

₹7,944 Cr

P/E ratio

25.33

P/B ratio

9.23

Dividend yield

Not available

ROE

Not available

RSI 14

72.47

1Y return

Not available

Sanofi India Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Sanofi India Limited (SANOFI) stock page cover?

Sanofi India Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SANOFI?

Sanofi India Limited is currently shown with a delayed price near ₹3,450.8, P/E 25.33.

Does the SANOFI page provide investment advice?

No. The SANOFI page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

SANOFICONR

Sanofi Consumer Healthcare India Limited · Healthcare

SENORES

Senores Pharmaceuticals Limited · Healthcare

SMSPHARMA

SMS Pharmaceuticals Limited · Healthcare

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Master AI-assisted stock research on Indian equities. Learn how to construct grounded financial queries, audit concall guidance, verify filing citations, and avoid ungrounded AI hallucinations.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Sanofi India Limited operates in Drug Manufacturers - General within the Healthcare sector. The company's primary business segment is pharmaceuticals, with operations predominantly focused on India. Area of operation: Primarily India, with exports to over 60 countries.

Drug Manufacturers - GeneralFounded:1956CEO/MD:Rodolfo H. C. SequeiraHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

Key products include Combiflam, Lantus, Cardace, and Allegra, serving therapeutic areas like diabetes, cardiology, and pain care.

What Looks Strong

QualityQuality score is supported by healthy return on equity (ROE 36.5%).
Cash FlowOperating cash flow was 1.47× total net profit in CY24.
ValuationTrailing P/E is 25.3×. The valuation score is 71/100.

What to Watch

RevenueRevenue declined about 29% in CY24 (consolidated: ₹2,851 cr → ₹2,013 cr). Watch whether the next results confirm a trend or a one-off.
EarningsNet profit fell about 48% in CY24 (consolidated: ₹603 cr → ₹314 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~26.8% to ~22.6% in CY24 (consolidated). Watch input costs and pricing in the next two results.
MarketShares have lagged the Nifty 500 by 31.6 percentage points annualized over three years.

Reports a single operating segment in its results filings.
Sanofi India develops, manufactures, and markets a wide portfolio of prescription drugs, over-the-counter products, and vaccines.
The company generates revenue by selling these pharmaceutical products to hospitals, pharmacies, and healthcare providers throughout India.

CY24 (consolidated): revenue ₹2,013 cr, down 29% from ₹2,851 cr in CY23; net profit ₹314 cr, down 48% from ₹603 cr in CY23.
CY24 (consolidated): operating cash flow ₹462 cr (1.5× net profit); debt/equity 0.02×.